Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bolt Biotherapeutics
Biotech
Bolt halves workforce again to find cash for cancer drug readout
Bolt has halved its workforce for the second time in two years as the oncology biotech delays a readout of its immunotherapy.
James Waldron
Oct 2, 2025 6:45am
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
May 17, 2024 8:30am
Bolt Bio halves workforce, while Tenaya lays off 5th of staff
May 15, 2024 7:17am
Biotechs cut pipeline prospects to focus on priority programs
Aug 11, 2022 9:43am
Bolt cans candidate over toxicity, pauses work to extend runway
Aug 11, 2022 7:50am
Genmab joins with Bolt to develop bispecific immune stimulators
Jun 2, 2021 8:00am
